Press

AUSTIN, Texas – Senseye, a pioneering diagnostic company dedicated to addressing America’s most critical mental health challenges, including Post Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD), announced the launch of a comprehensive Phase 3 clinical study for its revolutionary PTSD diagnostic tool, with the goal of obtaining FDA authorization as the first objective diagnostic test for PTSD. This landmark study represents a potentially significant advancement in mental health care.

Details of the trial are available at: mentalhealthstudy.org.

The clinical trial is open to people who qualify in most states. As most people in this trial can take part virtually, you can be part of important mental health research without leaving your house. A small number of people may still need to visit a clinic, but for most, the whole study can be done at home.

The study is open to adults 18 years of age and older experiencing symptoms commonly associated with PTSD, including sleep disturbances, intrusive thoughts, and recurring traumatic memories. A PTSD diagnosis is not required.

“Mental health challenges represent one of the most pressing issues facing our nation today, and our diagnostic tool stands at the forefront of addressing these critical needs,” David Zakariaie, CEO of Senseye. “Our revolutionary app is specifically designed to provide objective, reliable diagnoses of PTSD and other mental health conditions. We thank everyone willing to participate in our trial.”

The study’s inclusive design welcomes a broad range of participants who meet specific criteria.

• Must be 18 years of age or older and experience PTSD-like symptoms such as difficulty sleeping, intrusive thoughts, or recurring memories.
• Need access to an iPhone 13 or newer model.
• Participants will be paid up to $300 for their time and effort.

However, certain conditions exclude participation to ensure safety and data integrity. Individuals with epilepsy or dementia, autism or other cognitive disorders are not eligible. The study also excludes those who have used hard drugs (excluding cannabis and alcohol) in the last two weeks or are currently taking beta or alpha blockers – commonly prescribed medications that could potentially interfere with the diagnostic tool’s accuracy.

In addition to the primary digital platform, the company has established a physical research site in Idaho, where local participants may take part in person.

This is an experimental diagnostic tool and has not been proven to conclusively work. Trial participation includes both benefits and risks.

About Senseye, Inc.
Senseye, Inc. is developing the world’s first non-invasive mental health visibility platform. Through computer vision and AI, the company translates ocular responses into objective metrics for diagnosing and monitoring mental health conditions. Backed by clinical trials with the U.S. Department of Defense and leading academic institutions, Senseye is redefining how mental health is measured and managed. If you can see it & measure it, you can empower the world’s understanding of mental health.

For more information, please visit senseye.co

Media Contact:
Ashley Lawless
ashley.lawless@teamhighwire.com